---
title: "Eli Lilly Plans Women’s Health Push Using GLP-1 Windfall"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298579681.md"
description: "Eli Lilly & Co. has been preparing a broader move into women’s health, assembling experts and seeking new medicines for conditions including bone health and endometriosis, according to Bloomberg. The company’s GLP-1 windfall is expected to help fund the investments, people familiar with the matter said."
datetime: "2026-09-10T10:36:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298579681.md)
  - [en](https://longbridge.com/en/news/298579681.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298579681.md)
generator: "portal-rs"
---

# Eli Lilly Plans Women’s Health Push Using GLP-1 Windfall

Eli Lilly & Co. has been preparing a broader move into women’s health, assembling experts and seeking new medicines for conditions including bone health and endometriosis, according to Bloomberg. The company’s GLP-1 windfall is expected to help fund the investments, people familiar with the matter said.

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)

## Related News & Research

- [Eli Lilly and Company $LLY Shares Purchased by Integrated Wealth Concepts LLC](https://longbridge.com/en/news/298698438.md)
- [Eli Lilly and QurCan sign genetic medicine deal](https://longbridge.com/en/news/299162046.md)
- [Circle Pharma raises $92.5 million in Series E funding led by Column Group](https://longbridge.com/en/news/299181925.md)
- [RevelAi Health's MSK ACCESS Listed in Medicare's ACCESS Directory](https://longbridge.com/en/news/299087631.md)
- [Maloon Powers Pitre Higgins & Dennehy LLC Buys Shares of 908 Eli Lilly and Company $LLY](https://longbridge.com/en/news/298282618.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**